Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Clinical-trials-phase-ii symbols : LLY save search
We Don’t Know What We Don’t Know: LGBTQIA+ Patient Data and the Struggle for ...
Published: 2024-02-22 (Crawled : 12:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.59%
H: 1.11%
C: 0.92%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 2.37%
H: 1.51%
C: 0.79%
BioAge Labs Announces Plans for Phase 2 Trial of First-in-Class Apelin Receptor Agonist BGE-105/Azelaprag Co-Administered With Tirzepatide for Treatment of Obesity, in Collaboration With Lilly’s Chorus Organization
Published: 2023-10-26 (Crawled : 00:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -1.68%
H: 0.0%
C: 0.0%
bge-105 agonist treatment collaboration trial tirzepatide
Sermonix Pharmaceuticals Announces Article Comparing ‘Traditional’ to ‘Just-in-Time’ Trial Enrollment Models Is Published in JCO Clinical Cancer Informatics
Published: 2023-06-26 (Crawled : 18:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.4%
H: 0.0%
C: -2.69%
LGND | $72.59 0.1% 0.1% 140K
|
Health Technology
|
| O: -0.3%
H: 1.85%
C: -0.84%
cancer pharmaceuticals trial
Veru Announces Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with COVID-19 on Supplemental Oxygen at Infectious Disease Week 2022
Published: 2022-10-24 (Crawled : 14:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.01%
H: 2.19%
C: 1.07%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 0.63%
H: 0.6%
C: -3.2%
covid-19 treatment sabizabulin disease oxygen week presentation
Sermonix Pharmaceuticals’ Phase 2 Lasofoxifene Trial Poster Receives a GRASP Advocate Choice Award, Selected for Post-ASCO Patient Advocate Investigator Discussions
Published: 2022-06-08 (Crawled : 15:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 3.02%
H: 0.98%
C: 0.34%
LGND | $72.59 0.1% 0.1% 140K
|
Health Technology
|
| O: -1.26%
H: 1.8%
C: -0.71%
trial phase 2
Veru Announces Oral Late-Breaking Presentation of Phase 2 Data of Sabizabulin for the Treatment of Hospitalized Severe COVID-19 Patients
Published: 2022-04-25 (Crawled : 14:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -3.29%
H: 2.58%
C: 2.31%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: 0.89%
H: 27.06%
C: 24.67%
covid-19 treatment sabizabulin presentation phase 2
Veru Announces the Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2022 ASCO Genitourinary Cancers Symposium
Published: 2022-02-17 (Crawled : 14:30) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -1.88%
VERU | $1.305 -8.1% -8.81% 2.6M
|
Health Technology
|
| O: -0.96%
H: 0.88%
C: -3.38%
prostate cancer symposium state phase 1b presentation asco phase 1 cancer sabizabulin phase 2b
Neurimmune and TVM Capital Life Science Announce the Initiation of AL-S Pharma's Phase 2 Study of AP-101 for the Treatment of ALS
Published: 2021-11-18 (Crawled : 21:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 2.14%
H: 0.69%
C: -0.26%
treatment phase 2 life science als
At Week 104, 75% of Patients with Ulcerative Colitis Taking Mirikizumab Maintained Symptomatic Remission in Phase 2 Study
Published: 2021-10-01 (Crawled : 14:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.12%
H: 0.0%
C: 0.0%
phase 2 ulcerative colitis
AnHeart and Innovent Announce Interim Data from Phase Ⅱ Trial (TRUST) of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting
Published: 2021-09-27 (Crawled : 13:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -1.21%
H: 0.47%
C: -1.55%
heart positive trial
Data from NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients Published in Clinical Infectious Diseases
Published: 2021-09-01 (Crawled : 12:15) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.1%
H: 0.09%
C: -0.44%
RIGL | $1.07 1.91% 1.87% 810K
|
Health Technology
|
| O: -0.26%
H: 8.84%
C: 8.44%
covid disease phase 2 infectious disease trial
Eli Lilly Hopes to Clear Runway for AD Drug with New Amyloid Data
Published: 2021-07-30 (Crawled : 14:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
drug
Lilly releases donanemab data that demonstrated relationship between reduction of amyloid plaque and slowing of cognitive decline
Published: 2021-07-29 (Crawled : 20:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.4%
H: 0.3%
C: -0.88%
plague
Clinical Catch-Up: July 5-9
Published: 2021-07-12 (Crawled : 14:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.98%
H: 1.2%
C: 0.36%
Clinical Catch-Up: June 14-18
Published: 2021-06-21 (Crawled : 16:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.25%
H: 2.13%
C: 1.63%
Innovent Announces First Patient Dosed in the Phase II Basket Trial of Taletrectinib for Solid Tumors with NTRK Fusion
Published: 2021-06-17 (Crawled : 01:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.22%
H: 1.28%
C: 0.88%
solid tumors trial
First Patient Dosed in Phase II Basket Trial of Taletrectinib for Solid Tumors with NTRK Fusion
Published: 2021-06-17 (Crawled : 01:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.22%
H: 1.28%
C: 0.88%
solid tumors trial
Positive Topline Data Shows Fostamatinib Meets Primary Endpoint of Safety in Phase 2 Clinical Trial in Hospitalized Patients with COVID-19
Published: 2021-04-13 (Crawled : 12:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.35%
H: 1.36%
C: 0.75%
RIGL | $1.07 1.91% 1.87% 810K
|
Health Technology
|
| O: 13.27%
H: 5.14%
C: 3.14%
covid phase 2 positive topline trial
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.